Top

Published in:

01-01-2006 | Research Article

Use of Positron Emission Tomography to Target Prostate Cancer Gene Therapy by Oncolytic Herpes Simplex Virus

Authors: Michael Mullerad, MD, David P. Eisenberg, MD, Timothy J. Akhurst, MD, Prasad S. Adusumilli, MD, Christopher C. Riedl, MD, Amit Bhargava, MD, Mithat Gonen, PhD, Ronald Finn, PhD, Peter T. Scardino, MD, Yuman Fong, MD

Published in: Molecular Imaging and Biology | Issue 1/2006

Abstract

Herpes simplex virus (HSV) oncolytic gene therapy is a promising treatment modality against cancer. We have demonstrated that androgen-induced cellular changes enhance oncolytic viral replication and improve efficacy in the treatment of androgen-dependent prostate cancer cell line. Imaging of changes in 2-deoxy-2-[F-18]fluoro-d-glucose (FDG) uptake by positron emission tomography (PET) is a sensitive method of detecting altered cellular metabolism involved in cancer therapy. We therefore hypothesized that FDG-PET can predict tumor response to oncolytic HSV therapy. In this study, androgen increased cell kill (74%) in vitro and enhanced viral yield (2.4-fold) in vivo following HSV therapy. This enhanced efficacy was predicted by high FDG accumulation in intact animals compared to low FDG uptake following orchiectomy (p = 0.002). This proof-of-concept study provides the mechanistic basis for selecting patients for targeted oncolytic viral therapy by means of a noninvasive molecular imaging method in the treatment of prostate cancer.

Toda M, Rabkin SD, Martuza RL (1998) Treatment of human breast cancer in a brain metastatic model by G207, a replication-competent multimutated herpes simplex virus 1. Hum Gene Ther 9:2177–2185PubMed

Walker JR, McGeagh KG, Sundaresan P, Jorgensen TJ, Rabkin SD, Martuza RL (1999) Local and systemic therapy of human prostate adenocarcinoma with the conditionally replicating herpes simplex virus vector G207. Hum Gene Ther 10(13):2237–2243. Sep 1CrossRefPubMed

Mineta T, Rabkin SD, Yazaki T, Hunter WD, Martuza RL (1995) Attenuated multi-mutated herpes simplex virus-1 for the treatment of malignant gliomas. Nat Med 1(9):938–943. SepCrossRefPubMed

Ebright MI, Zager JS, Malhotra S, Delman KA, Weigel TL, Rusch VW, et al. (2002) Replication-competent herpes virus NV1020 as direct treatment of pleural cancer in a rat model. J Thorac Cardiovasc Surg 124(1):123–129. JulCrossRefPubMed

Carew JF, Kooby DA, Halterman MW, Federoff HJ, Fong Y (1999) Selective infection and cytolysis of human head and neck squamous cell carcinoma with sparing of normal mucosa by a cytotoxic herpes simplex virus type 1 (G207). Hum Gene Ther 10(10):1599–1606. Jul 1CrossRefPubMed

Galvan V, Roizman B (1998) Herpes simplex virus 1 induces and blocks apoptosis at multiple steps during infection and protects cells from exogenous inducers in a cell-type-dependent manner. Proc Natl Acad Sci USA 95(7):3931–3936. Mar 31CrossRefPubMed

Roizman B (1996) The function of herpes simplex virus genes: A primer for genetic engineering of novel vectors. Proc Natl Acad Sci USA 93(21):11307–11312CrossRefPubMed

Galvan V, Brandimarti R, Munger J, Roizman B (2000) Bcl-2 blocks a caspase-dependent pathway of apoptosis activated by herpes simplex virus 1 infection in HEp-2 cells. J Virol 74(4):1931–1938. FebCrossRefPubMed

Cozzi PJ, Burke PB, Bhargav A, Heston WD, Huryk B, Scardino PT, et al. (2002) Oncolytic viral gene therapy for prostate cancer using two attenuated, replication-competent, genetically engineered herpes simplex viruses. Prostate 53(2):95–100. Oct 1CrossRefPubMed

10.

Jemal A, Tiwari RC, Murray T, Ghafoor A, Samuels A, Ward E, et al. (2004) Cancer statistics, 2004. CA Cancer J Clin 54(1):8–29. JanPubMedCrossRef

11.

Eastham JA, Kattan MW, Rogers E, Goad JR, Ohori M, Boone TB, et al. (1996) Risk factors for urinary incontinence after radical prostatectomy. J Urol 156(5):1707–1713. NovCrossRefPubMed

12.

Catalona WJ, Carvalhal GF, Mager DE, Smith DS (1999) Potency, continence and complication rates in 1,870 consecutive radical retropubic prostatectomies. J Urol 162(2):433–438. AugCrossRefPubMed

13.

Wei JT, Dunn RL, Marcovich R, Montie JE, Sanda MG (2000) Prospective assessment of patient reported urinary continence after radical prostatectomy. J Urol 164(3 Pt 1):744–748. SepCrossRefPubMed

14.

Walsh PC (2000) Patient-reported urinary continence and sexual function after anatomic radical prostatectomy. J Urol 164(1):242. JulPubMedCrossRef

15.

Goluboff ET, Saidi JA, Mazer S, Bagiella E, Heitjan DF, Benson MC, et al. (1998) Urinary continence after radical prostatectomy: The Columbia experience. J Urol 159(4):1276–1280. AprCrossRefPubMed

16.

Rabbani F, Stapleton AM, Kattan MW, Wheeler TM, Scardino PT (2000) Factors predicting recovery of erections after radical prostatectomy. J Urol 164(6):1929–1934. DecCrossRefPubMed

17.

Ott K, Fink U, Becker K, Stahl A, Dittler HJ, Busch R, et al. (2003) Prediction of response to preoperative chemotherapy in gastric carcinoma by metabolic imaging: Results of a prospective trial. J Clin Oncol 21(24):4604–4610. Dec 15CrossRefPubMed

18.

Bennett JJ, Tjuvajev J, Johnson P, Doubrovin M, Akhurst T, Malholtra S, et al. (2001) Positron emission tomography imaging for herpes virus infection: Implications for oncolytic viral treatments of cancer. Nat Med 7(7):859–863CrossRefPubMed

19.

Jacobs A, Voges J, Reszka R, Lercher M, Gossmann A, Kracht L, et al. (2001) Positron-emission tomography of vector-mediated gene expression in gene therapy for gliomas. Lancet 358(9283):727–729. Sep 1CrossRefPubMed

20.

Turlakow A, Larson SM, Coakley F, Akhurst T, Gonen M, Macapinlac HA, et al. (2001) Local detection of prostate cancer by positron emission tomography with 2-fluorodeoxyglucose: Comparison of filtered back projection and iterative reconstruction with segmented attenuation correction. Q J Nucl Med 45(3):235–244. SepPubMed

21.

Agus DB, Golde DW, Sgouros G, Ballangrud A, Cordon-Cardo C, Scher HI (1998) Positron emission tomography of a human prostate cancer xenograft: Association of changes in deoxyglucose accumulation with other measures of outcome following androgen withdrawal. Cancer Res 58(14):3009–3014. Jul 15PubMed

22.

Kooby DA, Carew JF, Halterman MW, Mack JE, Bertino JR, Blumgart LH, et al. (1999) Oncolytic viral therapy for human colorectal cancer and liver metastases using a multi-mutated herpes simplex virus type-1 (G207). FASEB J 13(11):1325–1334. AugPubMed

23.

Wong RJ, Joe JK, Kim SH, Shah JP, Horsburgh B, Fong Y (2002) Oncolytic herpesvirus effectively treats murine squamous cell carcinoma and spreads by natural lymphatics to treat sites of lymphatic metastases. Hum Gene Ther 13(10):1213–1223. Jul 1CrossRefPubMed

24.

Oyama M, Ohigashi T, Hoshi M, Murai M, Uyemura K, Yazaki T (2000) Oncolytic viral therapy for human prostate cancer by conditionally replicating herpes simplex virus 1 vector G207. Jpn J Cancer Res 91(12):1339–1344. DecPubMed

25.

Duffy MJ (2005) Predictive markers in breast and other cancers: A review. Clin Chem 51(3):494–503. MarCrossRefPubMed

26.

Kim KS, Jeong JY, Kim YC, Na KJ, Kim YH, Ahn SJ, et al. (2005) Predictors of the response to gefitinib in refractory non-small cell lung cancer. Clin Cancer Res 11(6):2244–2251. Mar 15CrossRefPubMed

Title: Use of Positron Emission Tomography to Target Prostate Cancer Gene Therapy by Oncolytic Herpes Simplex Virus
Authors: Michael Mullerad, MD
David P. Eisenberg, MD
Timothy J. Akhurst, MD
Prasad S. Adusumilli, MD
Christopher C. Riedl, MD
Amit Bhargava, MD
Mithat Gonen, PhD
Ronald Finn, PhD
Peter T. Scardino, MD
Yuman Fong, MD
Publication date: 01-01-2006
Publisher: Springer-Verlag
Published in: Molecular Imaging and Biology / Issue 1/2006
Print ISSN: 1536-1632
Electronic ISSN: 1860-2002
DOI: https://doi.org/10.1007/s11307-005-0028-x

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Use of Positron Emission Tomography to Target Prostate Cancer Gene Therapy by Oncolytic Herpes Simplex Virus

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2006

Positron Emission Tomography/Computed Tomography with F-18-fluorocholine for Restaging of Prostate Cancer Patients: Meaningful at PSA < 5 ng/ml?

Longitudinal MicroPET Imaging of Brain Tumor Growth with F-18-labeled RGD Peptide

Reduction of Brown Fat 2-Deoxy-2-[F-18]fluoro-d-glucose Uptake by Controlling Environmental Temperature Prior to Positron Emission Tomography Scan

Usefulness of 3′-[F-18]Fluoro-3′-deoxythymidine with Positron Emission Tomography in Predicting Breast Cancer Response to Therapy

Combined I-124 Positron Emission Tomography/Computed Tomography Imaging of NIS Gene Expression in Animal Models of Stably Transfected and Intravenously Transfected Tumor

Synthesis and Positron Emission Tomography Evaluation of Three Norepinephrine Transporter Radioligands: [C-11]Desipramine, [C-11]Talopram and [C-11]Talsupram